800-Patient study tracks pancreatic cancer risk in hereditary pancreatitis
NCT ID NCT07413029
First seen Feb 19, 2026 · Last updated Jun 16, 2026 · Updated 13 times
Summary
This study follows 800 people who carry a PRSS1 gene mutation, which can cause hereditary pancreatitis. Researchers want to learn how often pancreatic cancer develops in this group and how the disease progresses over time. Participants are identified through genetic testing and followed by their regular doctors. The study does not test a new treatment, but aims to better understand the long-term health risks for people with this genetic condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY PANCREATITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
REBOURS
RECRUITINGClichy-sous-Bois, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.